LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.

RBC Capital Markets analysts believe Eli Lilly’s upcoming TRAILBLAZER-3 trial data on Kisunla could unlock a vast, largely untapped segment of the Alzheimer’s treatment market and pave the way for ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition by the world’s most valuable drugmaker as it seeks to boost its pipeline of ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

The U.S. Department of Agriculture considers vaccinating poultry against bird flu amidst a major animal-health crisis, with ...

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

Eli Lilly acquires Verve Therapeutics, Inc. for $1B to advance gene-editing therapies like VERVE-102, targeting ASCVD. Click for more on LLY and VERV.

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Sales of Eli Lilly’s (NYSE: LLY) Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the country following its commercial ...